Gilead re­leas­es an­oth­er round of murky remde­sivir re­sults

A month af­ter the NIH de­clared the first tri­al on remde­sivir in Covid-19 a suc­cess, Gilead is out with new re­sults on their an­tivi­ral. But al­though the study met one of its pri­ma­ry end­points, the da­ta are like­ly to on­ly add to a grow­ing de­bate over how ef­fec­tive the drug ac­tu­al­ly is.

In a Phase III tri­al, pa­tients giv­en a 5-day dose of remde­sivir were 65% more like­ly to show “clin­i­cal im­prove­ment” com­pared to an arm giv­en stan­dard-of-care. The tri­al, though, gave lit­tle in­di­ca­tion for whether the drug had an im­pact on key end­points such as sur­vival or time-to-re­cov­ery. And in a sur­pris­ing twist, a 10-day dos­ing arm of remde­sivir didn’t lead to a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment over stan­dard of care.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.